Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maurie Markman

Showing results (41-50 of 413) with videos related to

Pageof 42
Sort By:
Cancer|March 6, 2008
An ethical argument in support of interactions between developing world countries and pharmaceutical/biotechnology companies involved in oncology drug developmentMaurie Markman
Cancer Investigation|February 9, 2008
"Conflict-of-interest" and participation in IRB deliberations: an alternative perspectiveMaurie Markman
Oncology|June 10, 2008
The promise and perils of 'targeted therapy' of advanced ovarian cancerMaurie Markman
MD Advisor : a Journal for New Jersey Medical Community|September 10, 2019
Precision Cancer MedicineMaurie Markman
Gynecologic Oncology|February 1, 2008
Evidence-based chemotherapy administration in advanced ovarian cancer: an impressive past, a disquieting present and an uncertain futureMaurie Markman
Current Oncology Reports|March 2, 2006
Cancer survivorship: the concept and the increasingly recognized realityMaurie Markman
Current Oncology Reports|February 11, 2014
Dangers of "confirmatory" cancer trials that fail to actually test the original hypothesisMaurie Markman
Current Oncology Reports|March 28, 2008
The increasingly complex world of cancer patient advocacy organizationsMaurie Markman
Current Oncology Reports|February 9, 2006
Turning cervix cancer into a "rare disease": is society prepared to do what is required to make this a reality?Maurie Markman
Cancer Investigation|February 10, 2006
Another example of the highly variable clinical course of recurrent/resistant/persistent ovarian cancerMaurie Markman
Pageof 42

Showing results (41-50 of 413) with videos related to

Sort By:
Pageof 42
Cancer|March 6, 2008
An ethical argument in support of interactions between developing world countries and pharmaceutical/biotechnology companies involved in oncology drug developmentMaurie Markman
Cancer Investigation|February 9, 2008
"Conflict-of-interest" and participation in IRB deliberations: an alternative perspectiveMaurie Markman
Oncology|June 10, 2008
The promise and perils of 'targeted therapy' of advanced ovarian cancerMaurie Markman
MD Advisor : a Journal for New Jersey Medical Community|September 10, 2019
Precision Cancer MedicineMaurie Markman
Gynecologic Oncology|February 1, 2008
Evidence-based chemotherapy administration in advanced ovarian cancer: an impressive past, a disquieting present and an uncertain futureMaurie Markman
Current Oncology Reports|March 2, 2006
Cancer survivorship: the concept and the increasingly recognized realityMaurie Markman
Current Oncology Reports|February 11, 2014
Dangers of "confirmatory" cancer trials that fail to actually test the original hypothesisMaurie Markman
Current Oncology Reports|March 28, 2008
The increasingly complex world of cancer patient advocacy organizationsMaurie Markman
Current Oncology Reports|February 9, 2006
Turning cervix cancer into a "rare disease": is society prepared to do what is required to make this a reality?Maurie Markman
Cancer Investigation|February 10, 2006
Another example of the highly variable clinical course of recurrent/resistant/persistent ovarian cancerMaurie Markman
Pageof 42